5 Stocks Dominating The Market Today

2. Kodiak Sciences Inc. (NASDAQ:KOD)

Kodiak Sciences soared by 74.77 percent on Thursday to finish at $39.76 apiece, as investors took heart from the strong results of its clinical study for its diabetic retinopathy treatment.

In an updated report, Kodiak Sciences Inc. (NASDAQ:KOD) said that 62.5 percent of the enrolled patients achieved a more than 2-step improvement in diabetic retinopathy severity score, as compared with 3.3 percent of the sham group.

The patients were randomized to receive either a sham injection or Zenkuda via intravitreal injection at progressively extended intervals. Zenkuda also showed an 85-percent risk reduction in sight-threatening complications.

The drug candidate also demonstrated favorable safety and was well tolerated in the study, with a 0 percent intraocular inflammation rate and a 2.3 percent cataract adverse event rate, versus 1.6 percent with sham.

“We are very pleased to see that GLOW2 demonstrated a high degree of internal consistency across all datapoints. Importantly, GLOW2 also demonstrated strong external consistency when contextualized with GLOW1. Taken together, the combined GLOW1 and GLOW2 data package speaks volumes about the robustness of the data and the operational approach the team brought to the conduct of both studies,” Kodiak Sciences Inc. (NASDAQ:KOD) Chief Medical Officer J. Pablo Velazquez-Martin said.